These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 25651256)

  • 21. [To the optimization and evidence of current chemotherapy regimens for pulmonary tuberculosis].
    Mishin VIu; Chukanov VI; Vasil'eva IA
    Probl Tuberk Bolezn Legk; 2004; (8):7-11. PubMed ID: 15478548
    [No Abstract]   [Full Text] [Related]  

  • 22. Pharmacokinetics of moxifloxacin and linezolid during and after pregnancy in a patient with multidrug-resistant tuberculosis.
    Van Kampenhout E; Bolhuis MS; Alffenaar JC; Oswald LM; Kerstjens HA; de Lange WC; van der Werf TS; Akkerman OW
    Eur Respir J; 2017 Mar; 49(3):. PubMed ID: 28331037
    [No Abstract]   [Full Text] [Related]  

  • 23. Moxifloxacin is an effective and safe candidate agent for tuberculosis treatment: a meta-analysis.
    Xu P; Chen H; Xu J; Wu M; Zhu X; Wang F; Chen S; Xu J
    Int J Infect Dis; 2017 Jul; 60():35-41. PubMed ID: 28495364
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A Phase 2 Randomized Trial of a Rifapentine plus Moxifloxacin-Based Regimen for Treatment of Pulmonary Tuberculosis.
    Conde MB; Mello FC; Duarte RS; Cavalcante SC; Rolla V; Dalcolmo M; Loredo C; Durovni B; Armstrong DT; Efron A; Barnes GL; Marzinke MA; Savic RM; Dooley KE; Cohn S; Moulton LH; Chaisson RE; Dorman SE
    PLoS One; 2016; 11(5):e0154778. PubMed ID: 27159505
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Fluoroquinolones for treating tuberculosis.
    Ziganshina LE; Vizel AA; Squire SB
    Cochrane Database Syst Rev; 2005 Jul; (3):CD004795. PubMed ID: 16034951
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Moxifloxacin Replacement in Contemporary Tuberculosis Drug Regimens Is Ineffective against Persistent Mycobacterium tuberculosis in the Cornell Mouse Model.
    Liu Y; Pertinez H; Davies GR; Gillespie SH; Coates AR; Hu Y
    Antimicrob Agents Chemother; 2018 Jul; 62(7):. PubMed ID: 29661869
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [The treatment of tuberculosis. I. Mycobacterial subpopulations in the lesions and antitubercular drugs].
    Corlan E
    Pneumoftiziologia; 1992; 41(4):231-42. PubMed ID: 1339503
    [No Abstract]   [Full Text] [Related]  

  • 28. First Insight Into the Fluoroquinolone and Aminoglycoside Resistance of Multidrug-Resistant
    Varghese B; Al-Hajoj S
    Am J Trop Med Hyg; 2017 May; 96(5):1066-1070. PubMed ID: 28500800
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Synergistic activities of clofazimine with moxifloxacin or capreomycin against Mycobacterium tuberculosis in China.
    Li G; Xu Z; Jiang Y; Liu H; Zhao LL; Li M; Xu D; Zhao X; Liu Z; Wang R; Wan K
    Int J Antimicrob Agents; 2019 Nov; 54(5):642-646. PubMed ID: 31200023
    [TBL] [Abstract][Full Text] [Related]  

  • 30. New drug combination may shorten tuberculosis treatment, study says.
    Mayor S
    BMJ; 2015 Mar; 350():h1518. PubMed ID: 25788408
    [No Abstract]   [Full Text] [Related]  

  • 31. [Dynamics of the release of bacilli and the closing of caverns in newly identified tuberculosis patients undergoing different chemotherapeutic regimens].
    Muratov VV; Pashkov IuN; Pospelov VV
    Probl Tuberk; 1981 Dec; (12):30-4. PubMed ID: 6801646
    [No Abstract]   [Full Text] [Related]  

  • 32. [Present and future in the use of anti-tubercular drugs].
    Didilescu C; Craiova UM
    Pneumologia; 2011; 60(4):198-201. PubMed ID: 22420168
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Morphologic and biochemical changes in Mycobacterium tuberculosis during chemotherapy].
    Khomenko AG; Fadeeva NI; Golyshevskaia VI
    Probl Tuberk; 1983 Jul; (7):48-54. PubMed ID: 6415652
    [No Abstract]   [Full Text] [Related]  

  • 34. [L-forms of Mycobacterium tuberculosis during chemotherapy of patients with chronic destructive pulmonary tuberculosis].
    Karachunskiĭ MA; Dorozhkova IR; Kaminskaia AA; Abdullaeva ET
    Probl Tuberk; 1983 Jul; (7):38-43. PubMed ID: 6415651
    [No Abstract]   [Full Text] [Related]  

  • 35. [Use of molecular-biological microchip TB-BIOCHIP-2 for detecting of Mycobacterium tuberculosis with multidrug resistance to fluoroquinolones in patients with new detected and chronic tuberculosis].
    Nosova EIu; Galkina KIu; Antonova OV; Garmash IuIu; Skotnikova OI; Moroz AM
    Vestn Ross Akad Med Nauk; 2008; (3):16-9. PubMed ID: 18421904
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Limited Effect of Later-Generation Fluoroquinolones in the Treatment of Ofloxacin-Resistant and Moxifloxacin-Susceptible Multidrug-Resistant Tuberculosis.
    Lee H; Ahn S; Hwang NY; Jeon K; Kwon OJ; Huh HJ; Lee NY; Kim CK; Koh WJ
    Antimicrob Agents Chemother; 2018 Feb; 62(2):. PubMed ID: 29203478
    [TBL] [Abstract][Full Text] [Related]  

  • 37. When is pulmonary tuberculosis cured?
    Buechner HA
    Lancet; 1982 Jun; 1(8287):1462. PubMed ID: 6123734
    [No Abstract]   [Full Text] [Related]  

  • 38. New tuberculosis therapy offers potential shorter treatment.
    Wkly Epidemiol Rec; 2006 Jan; 81(2):19-20. PubMed ID: 16671244
    [No Abstract]   [Full Text] [Related]  

  • 39. [Mycobacterium tuberculosis L forms in patients with pulmonary and pleural tuberculosis during antibacterial chemotherapy].
    Osiĭskiĭ IIu; Kotliar KD
    Vrach Delo; 1989 Sep; (9):55-6. PubMed ID: 2514488
    [No Abstract]   [Full Text] [Related]  

  • 40. [The effectiveness and safety of sparfloxacine in combined therapy for tuberculosis].
    Sokolova GB; Khaĭmenova TIa; Borisov SE; Lazareva IaV; Bogadel'nikova IV; Biron MG; Mozhokina GN; Tsibanev AA
    Probl Tuberk Bolezn Legk; 2007; (6):40-5. PubMed ID: 17674470
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.